MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Repligen Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

129.04 0.52

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

126.52

Max

130.45

Pagrindiniai rodikliai

By Trading Economics

Pajamos

40M

5.8M

Pardavimai

1.6M

169M

P/E

Sektoriaus vid.

466.89

39.564

Pelno marža

3.446

Darbuotojai

1,778

EBITDA

2.7M

36M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+37.68% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-07-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.1B

7.2B

Ankstesnė atidarymo kaina

128.52

Ankstesnė uždarymo kaina

129.04

Naujienos nuotaikos

By Acuity

33%

67%

78 / 376 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Repligen Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-09 15:46; UTC

Pagrindinės rinkos jėgos

BitMine Shares Fall After Closing of $250 Million Private Placement

2025-07-09 23:44; UTC

Rinkos pokalbiai

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

2025-07-09 23:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-09 23:42; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

2025-07-09 22:59; UTC

Rinkos pokalbiai

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

2025-07-09 22:59; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-09 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2025-07-09 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-09 20:26; UTC

Uždarbis

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

2025-07-09 19:18; UTC

Rinkos pokalbiai

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

2025-07-09 19:03; UTC

Rinkos pokalbiai

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

2025-07-09 18:31; UTC

Rinkos pokalbiai

Some Fed Officials Supported Considering July Cut -- Market Talk

2025-07-09 17:07; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

2025-07-09 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk -2-

2025-07-09 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-07-09 16:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2025-07-09 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-09 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-09 16:14; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-09 16:14; UTC

Rinkos pokalbiai

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

2025-07-09 16:14; UTC

Įsigijimai, susijungimai, perėmimai

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

2025-07-09 16:12; UTC

Rinkos pokalbiai

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

2025-07-09 16:08; UTC

Rinkos pokalbiai

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

2025-07-09 15:31; UTC

Pagrindinės rinkos jėgos

BitMine Shares Fall After Closing of $250M Private Placement

2025-07-09 15:31; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

2025-07-09 15:27; UTC

Rinkos pokalbiai

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

2025-07-09 14:36; UTC

Įsigijimai, susijungimai, perėmimai

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

2025-07-09 14:31; UTC

Įsigijimai, susijungimai, perėmimai

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

2025-07-09 14:26; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-07-09 14:26; UTC

Rinkos pokalbiai

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Akcijų palyginimas

Kainos pokytis

Repligen Corp Prognozė

Kainos tikslas

By TipRanks

37.68% į viršų

12 mėnesių prognozė

Vidutinis 177 USD  37.68%

Aukščiausias 207 USD

Žemiausias 130 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Repligen Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

14 ratings

10

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

125.31 / 140.7Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Strong Bearish Evidence

Rinkos nuotaikos

By Acuity

78 / 376 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Repligen Corp

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.